Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition

被引:3
作者
Minic Janicijevic, Slavica [1 ]
Jovanovic, Ivan P. [2 ]
Gajovic, Nevena M. [2 ]
Jurisevic, Milena M. [3 ]
Debnath, Monojit [4 ]
Arsenijevic, Nebojsa N. [2 ]
Borovcanin, Milica M. [5 ,6 ]
机构
[1] Univ Kragujevac, Fac Med Sci, Kragujevac 34000, Serbia
[2] Univ Kragujevac, Fac Med Sci, Ctr Mol Med & Stem Cell Res, Kragujevac 34000, Serbia
[3] Univ Kragujevac, Fac Med Sci, Dept Pharm, Kragujevac 34000, Serbia
[4] Natl Inst Mental Hlth & Neurosci, Dept Human Genet, Bangalore 560029, India
[5] Univ Kragujevac, Fac Med Sci, Dept Psychiat, Kragujevac 34000, Serbia
[6] Univ Kragujevac, Fac Med Sci, Dept Psychiat, Svetozara Markov 69, Kragujevac 34000, Serbia
来源
WORLD JOURNAL OF PSYCHIATRY | 2022年 / 12卷 / 09期
关键词
Schizophrenia; Galectin-3; Cytokines; Leukocytes; Antipsychotics; CYTOKINE; ACTIVATION; PSYCHOSIS; PATHWAYS; CELLS;
D O I
10.5498/wjp.v12.i9.1183
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
BACKGROUND Evidence suggests that cytokines cause immune disturbances, shape immunological sequelae later in life, and modulate the risk of schizophrenia (SC). Galectin-3 (Gal-3), a multifaceted molecule of the glycan family, is involved in the formation of the immunological synapse and modulates the signalling pathway and effector functions of T lymphocytes, which are major producers of cytokines. We have previously reported elevated serum Gal-3 levels in stable SC patients. However, Gal-3 as a link between cognitive functioning and inflammation has not yet been investigated in SC. AIM To investigate the relationship between serum Gal-3 levels and cognitive performance, serum cytokines, and white blood cell count in three-month stably treated SC patients. METHODS Twenty-seven patients with SC in remission and 18 healthy volunteers participated in this case-control and correlational study. Clinical assessment was performed using the Positive and Negative Syndrome Scale and the Montreal-Cognitive Assessment. The results of previously measured serum levels of Gal-3, interleukin (IL)-33, soluble suppression of tumorigenicity 2 (sST2), tumor necrosis factor-alpha (TNF-alpha), IL-6 and IL-17 were used for further statistical analyses, and IL-4, IL-23, IL-1 beta and transforming growth factor-beta (TGF-beta) were now additionally measured with a sensitive enzyme-linked immunosorbent assay. The number of leukocytes in the blood and the percentage of neutrophils, lymphocytes, and monocytes were determined with a standardized routine measurement procedure (Sysmex Technology). Statistical analyses were performed using SPSS 20.0 software. RESULTS We found no correlation between serum Gal-3 levels and cognitive functioning in SC patients. A positive correlation was found between the levels of Gal-3 and TNF-alpha (r = 0.476; P = 0.012), Gal-3 and IL-23 (r = 0.417; P = 0.031), and Gal-3 and sST2 (r = 0.402; P = 0.038). The binary logistic model, which included all nine cytokines measured in this patient sample, indicated the particular role of Gal-3 and TGF-beta in the duration of SC. In the stabilization phase of SC, we observed a moderate and negative correlation between serum Gal-3 levels and leukocytes (r = -0.449; P < 0.019). Additional linear regression analysis showed a positive correlation between Gal-3 expression and risperidone dose (F: 4.467; P < 0.045; r(2) = 0.396). CONCLUSION The combined activity of Gal-3 and proinflammatory cytokines, TGF-beta downregulation and lower counts of leukocytes influence the SC duration. Gal-3 likely manifests indirect immunometabolic regulation of cognition in SC.
引用
收藏
页码:1183 / 1193
页数:11
相关论文
共 49 条
  • [41] Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer
    Shimura, Tatsuo
    Shibata, Masahiko
    Gonda, Kenji
    Nakajima, Takahiro
    Chida, Shun
    Noda, Masaru
    Suzuki, Satoshi
    Nakamura, Izumi
    Ohki, Shinji
    Takenoshita, Seiichi
    [J]. BIOMEDICAL REPORTS, 2016, 5 (02) : 203 - 207
  • [42] Role of IL-6/RORC/IL-22 axis in driving Th17 pathway mediated immunopathogenesis of schizophrenia
    Subbanna, Manjula
    Shivakumar, Venkataram
    Talukdar, Pinku Mani
    Narayanaswamy, Janardhanan C.
    Venugopal, Deepthi
    Berk, Michael
    Varambally, Shivarama
    Venkatasubrarnanian, Ganesan
    Debnath, Monojit
    [J]. CYTOKINE, 2018, 111 : 112 - 118
  • [43] Antipsychotic Treatment of Acute Paranoid Schizophrenia Patients with Olanzapine Results in Altered Glycosylation of Serum Glycoproteins
    Telford, Jayne E.
    Bones, Jonathan
    McManus, Ciara
    Saldova, Radka
    Manning, Gwen
    Doherty, Margaret
    Leweke, F. Markus
    Rothermundt, Matthias
    Guest, Paul C.
    Rahmoune, Hassan
    Bahn, Sabine
    Rudd, Pauline M.
    [J]. JOURNAL OF PROTEOME RESEARCH, 2012, 11 (07) : 3743 - 3752
  • [44] Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review
    Trepanier, M. O.
    Hopperton, K. E.
    Mizrahi, R.
    Mechawar, N.
    Bazinet, R. P.
    [J]. MOLECULAR PSYCHIATRY, 2016, 21 (08) : 1009 - 1026
  • [45] Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
    Tyminska, Agata
    Kaplon-Cieslicka, Agnieszka
    Ozieranski, Krzysztof
    Budnik, Monika
    Wancerz, Anna
    Sypien, Piotr
    Peller, Michal
    Balsam, Pawel
    Opolski, Grzegorz
    Filipiak, Krzysztof J.
    [J]. DISEASE MARKERS, 2019, 2019
  • [46] Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
    Upthegrove, Rachel
    Manzanares-Teson, Nuria
    Barnes, Nicholas M.
    [J]. SCHIZOPHRENIA RESEARCH, 2014, 155 (1-3) : 101 - 108
  • [47] Wasyanto T, 2019, ACTA MED INDONES, V51, P311
  • [48] World Health Organization, 2018, International Statistical Classification of Diseases and Related Health Problems
  • [49] Innate immunity at the crossroads of healthy brain maturation and neurodevelopmental disorders
    Zengeler, Kristine E.
    Lukens, John R.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2021, 21 (07) : 454 - 468